Quantitative Detection and Resolution of BRAF V600 Status in Colorectal Cancer Using Droplet Digital PCR and a Novel Wild-Type Negative Assay

Journal of Molecular Diagnostics

Volumn 18, Issue 2, 2016, Pages 190-204

  Bidshahri, Roza ^a   Attali, Dean ^b   Fakhfakh, Kareem ^a   McNeil, Kelly ^c   Karsan, Aly ^c   Won, Jennifer R ^b   Wolber, Robert ^d   Bryan, Jennifer ^b   Hughesman, Curtis ^a   Haynes, Charles ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d LIONS GATE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FORMALDEHYDE; LOCKED NUCLEIC ACID; PARAFFIN; BRAF PROTEIN, HUMAN; DNA PROBE;

ARTICLE; CANCER PATIENT; CANCER SCREENING; CHIMERA; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA PROBE; GENE MUTATION; HUMAN; HUMAN TISSUE; METASTATIC COLORECTAL CANCER; POINT MUTATION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PROTO ONCOGENE; QUANTITATIVE ANALYSIS; SOMATIC MUTATION; WILD TYPE; ALLELE; COLORECTAL TUMOR; DNA MUTATIONAL ANALYSIS; GENETICS; LIMIT OF DETECTION; PATHOLOGY; PLASMID; PROCEDURES; STANDARDS; TUMOR CELL LINE; WORKFLOW;

ALLELES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA PROBES; HUMANS; LIMIT OF DETECTION; PARAFFIN EMBEDDING; PLASMIDS; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; WORKFLOW;

EID: 84960926682     PISSN: 15251578     EISSN: 19437811     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2015.09.003     Document Type: Article

References (61)

1. C. Tomasetti, L. Marchionni, M.A. Nowak, G. Parmigiani, and B. Vogelstein Only three driver gene mutations are required for the development of lung and colorectal cancers Proc Natl Acad Sci U S A 112 2015 118 123
2. L.B. Alexandrov, S. Nik-Zainal, D.C. Wedge, S.A.J.R. Aparicio, S. Behjati, A.V. Biankin, and et al. Signatures of mutational processes in human cancer Nature 500 2013 415 421
3. Y.E. Nikiforov, and M.N. Nikiforova Molecular genetics and diagnosis of thyroid cancer Nat Rev Endocrinol 7 2011 569 580
4. A.F. Gazdar Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors Oncogene 28 2009 S24 S31
5. M.G. Fakih Metastatic colorectal cancer: current state and future directions J Clin Oncol 33 2015 1809 1824
6. L. Bolton, A. Reiman, K. Lucas, J. Timms, and I.A. Cree KRAS mutation analysis by PCR: a comparison of two methods PLoS One 10 2015 e0115672
7. E.J. Baxter, L.M. Scott, P.J. Campbell, C. East, N. Fourouclas, S. Swanton, G.S. Vassiliou, A.J. Bench, E.M. Boyd, N. Curtin, M.A. Scott, W.N. Erber, A.R. Green Cancer Genome Project Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 2005 1054 1061
8. A. Marchetti, C. Martella, L. Felicioni, F. Barassi, S. Salvatore, A. Chella, P.P. Camplese, T. Iarussi, F. Mucilli, A. Mezzetti, F. Cuccurullo, R. Sacco, and F. Buttitta EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment J Clin Oncol 23 2005 857 865
9. M.B. Loughrey, P.M. Waring, A. Tan, M. Trivett, S. Kovalenko, V. Beshay, M.A. Young, G. McArthur, A. Boussioutas, and A. Dobrovic Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer Fam Cancer 6 2007 301 310
10. M. Sensi, G. Nicolini, C. Petti, I. Bersani, F. Lozupone, A. Molla, C. Veggetti, D. Nonaka, R. Mortarini, G. Parmiani, S. Fais, and A. Anichini Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma Oncogene 25 2006 3357 3364
11. J. Lasota, A. Kowalik, B. Wasag, Z.F. Wang, A. Felisiak-Golabek, T. Coates, J. Kopczynski, S. Gozdz, and M. Miettinen Detection of the BRAF V600E mutation in colon carcinoma critical evaluation of the imunohistochemical approach Am J Surg Pathol 38 2014 1235 1241
12. Y.S. Chang, K.T. Yeh, N.C. Hsu, S.H. Lin, T.J. Chang, and J.G. Chang Detection of N-, H-, and KRAS codons 12, 13 and 61 mutations with universal RAS primer multiplex PCR and N-, H- and KRAS-specific primer extension Clin Biochem 43 2010 296 301
13. D.H. Hovelson, A.S. McDaniel, A.K. Cani, B. Johnson, K. Rhodes, P.D. Williams, S. Bandla, G. Bien, P. Choppa, F. Hyland, R. Gottimukkala, G. Liu, M. Manivannan, J. Schageman, E. Ballesteros-Villagrana, C.S. Grasso, M.J. Quist, V. Yadati, A. Amin, J. Siddiqui, B.L. Betz, K.E. Knudsen, K.A. Cooney, F.Y. Feng, M.H. Roh, P.S. Nelson, C.J. Liu, D.G. Beer, P. Wyngaard, A.M. Chinnaiyan, S. Sadis, D.R. Rhodes, and S.A. Tomlins Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors Neoplasia 17 2015 385 399
14. C.I. Dumur Available Resources and Challenges for the Clinical Annotation of Somatic Variations Cancer Cytopathol 122 2014 730 736
15. J.K. Xuan, Y. Yu, T. Qing, L. Guo, and L.M. Shi Next-generation sequencing in the clinic: promises and challenges Cancer Lett 340 2013 284 295
16. G.J. Tsongalis, J.D. Peterson, F.B. de Abreu, C.D. Tunkey, T.L. Gallagher, L.D. Strausbaugh, W.A. Wells, and C.I. Amos Routine use of the Ion-Torrent AmpliSeq (TM) Cancer Hotspot Panel for identification of clinically actionable somatic mutations Clin Chem Lab Med 52 2014 707 714
17. A. Zehir, T. Mitchell, W.J. Cheng, A. Oultache, K. Nafa, M.E. Arcila, M.F. Berger, D.T. Cheng, and C.V. Hedvat A paired-sample analysis pipeline for removing artifacts in point mutation calls made from the Illumina TruSeq Amplicon Cancer Panel (TSACP) assay J Mol Diagn 15 2013 941 942
18. I. Kinde, J. Wu, N. Papadopoulos, K.W. Kinzler, and B. Vogelstein Detection and quantification of rare mutations with massively parallel sequencing Proc Natl Acad Sci U S A 108 2011 9530 9535
19. D.L. Lou, J.A. Hussmann, R.M. McBee, A. Acevedo, R. Andino, W.H. Press, and S.L. Sawyer High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing Proc Natl Acad Sci U S A 110 2013 19872 19877
20. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, and et al. Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
21. J.A. Curtin, J. Fridlyand, T. Kageshita, H.N. Patel, K.J. Busam, H. Kutzner, K.H. Cho, S. Aiba, E.B. Brocker, P.E. LeBoit, D. Pinkel, and B.C. Bastian Distinct sets of genetic alterations in melanoma N Engl J Med 353 2005 2135 2147
22. L. Yip, M.N. Nikiforova, S.E. Carty, J.H. Yim, M.T. Stang, M.J. Tublin, S.O. LeBeau, S.P. Hodak, J.B. Ogilvie, and Y.E. Nikiforov Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation Surgery 146 2009 1215 1223
23. C.P. Vaughn, S.D. Zobell, L.V. Furtado, C.L. Baker, and W.S. Samowitz Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer Genes Chromosomes Cancer 50 2011 307 312
24. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbe, T. Jouary, D. Schadendorf, A. Ribas, S.J. O'Day, J.A. Sosman, J.M. Kirkwood, A.M. Eggermont, B. Dreno, K. Nolop, J. Li, B. Nelson, J. Hou, R.J. Lee, K.T. Flaherty, G.A. McArthur Brim-3 Study Group Improved survival with vemurafenib in melanoma with braf v600e mutation N Engl J Med 364 2011 2507 2516
25. K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, J.A. Sosman, P.J. O'Dwyer, R.J. Lee, J.F. Grippo, K. Nolop, and P.B. Chapman Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
26. M.C. Ravnan, and M.S. Matalka Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma Clin Ther 34 2012 1474 1486
27. J.J. Luke, and F.S. Hodi Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma Oncologist 18 2013 717 725
28. L. Heinzerling, S. Kuhnapfel, D. Meckbach, M. Baiter, E. Kaempgen, P. Keikavoussi, G. Schuler, A. Agaimy, J. Bauer, A. Hartmann, F. Kiesewetter, and R. Schneider-Stock Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice Br J Cancer 108 2013 2164 2171
29. J.C. Rubinstein, M. Sznol, A.C. Pavlick, S. Ariyan, E. Cheng, A. Bacchiocchi, H.M. Kkluger, D. Narayan, and R. Halaban Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032 J Transl Med 8 2010 67
30. C.M. Lovly, K.B. Dahlman, L.E. Fohn, Z. Su, D. Dias-Santagata, D.J. Hicks, D. Hucks, E. Berry, C. Terry, M. Duke, Y.J. Su, T. Sobolik-Delmaire, A. Richmond, M.C. Kelley, C.L. Vnencak-Jones, A.J. Iafrate, J. Sosman, and W. Pao Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials PLoS One 7 2012 e35309
31. H. Yang, B. Higgins, K. Kolinsky, K. Packman, Z. Go, R. Iyer, S. Kolis, S. Zhao, R. Lee, J.F. Grippo, K. Schostack, M.E. Simcox, D. Heimbrook, G. Bollag, and F. Su RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models Cancer Res 70 2010 5518 5527
32. F. Di Nicolantonio, M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti, S. De Dosso, L. Mazzucchelli, M. Frattini, S. Siena, and A. Bardelli Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 2008 5705 5712
33. A. Prahallad, C. Sun, S. Huang, F. Di Nicolantonio, R. Salazar, D. Zecchin, R.L. Beijersbergen, A. Bardelli, and R. Bernards Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 483 2012 100 103
34. P. Minoo, M.P. Moyer, and J.R. Jass Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis J Pathol 212 2007 124 133
35. F. Pietrantonio, F. Petrelli, A. Coinu, M. Di Bartolomeo, K. Borgonovo, C. Maggi, M. Cabiddu, R. Iacovelli, I. Bossi, V. Lonati, M. Ghilardi, F. de Braud, and S. Barni Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis Eur J Cancer 51 2015 587 594
36. R.P. Tufano, G.V. Teixeira, J. Bishop, K.A. Carson, and M. Xing BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis Medicine (Baltimore) 91 2012 274 286
37. C.B. Hughesman, R.F.B. Turner, and C.A. Haynes Role of the heat capacity change in understanding and modeling melting thermodynamics of complementary duplexes containing standard and nucleobase-modified LNA Biochemistry 50 2011 5354 5368
38. C. Hughesman, K. Fakhfakh, R. Bidshahri, H.L. Lund, and C. Haynes A new general model for predicting melting thermodynamics of complementary and mismatched B-form duplexes containing locked nucleic acids: application to probe design for digital PCR detection of somatic mutations Biochemistry 54 2015 1338 1352
39. C.B. Hughesman, R.F. Turner, and C. Haynes Correcting for heat capacity and 5'-TA type terminal nearest neighbors improves prediction of DNA melting temperatures using nearest-neighbor thermodynamic models Biochemistry 50 2011 2642 2649
40. A. Untergasser, I. Cutcutach, T. Koressaer, J. Ye, B.C. Faircloth, M. Remm, and S.G. Rozen Primer3-new capabilities and interfaces Nucleic Acids Res 40 2012 e115
41. C.B. Hughesman, R.F.B. Turner, and C. Haynes Measuring, interpreting and modeling the stabilities and melting temperatures of B-form DNA that exhibits a two-state helix-to-coil transition U. von Stocker, L.A.M. van der Wielen, Biothermodynamics: The Role of Thermodynamics in Biochemical Engineering 2013 EPFL Press Lausanne, Switzerland 355 389
42. J. Ye, G. Coulouris, I. Zaretskaya, I. Cutcutache, S. Rozen, and T. Madden Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction BMC Bioinformatics 13 2012 134
43. T. Benaglia, D. Chauveau, D.R. Hunter, and D. Young Mixtools: an R package for analyzing finite mixture models J Stat Softw 32 2009 1 29 doi: 10.18637/jss.v032.i06
44. H. Halait, K. DeMartin, S. Shah, S. Soviero, R. Langland, S. Cheng, G. Hillman, L. Wu, and H.J. Lawrence Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma Diagn Mol Pathol 21 2012 1 8
45. J.M. Tuomi, F. Voorbraak, D.L. Jones, and J.M. Ruijter Bias in the Cq value observed with hydrolysis probe based quantitative PCR can be corrected with the estimated PCR efficiency value Methods 50 2010 313 322
46. P.M. Holland, R.D. Abramson, R. Watson, and D.H. Gelfand Detection of specific polymerase chain reaction product by utilizing the 5' to 3' exonuclease activity of Thermus aquaticus DNA polymerase Proc Natl Acad Sci U S A 88 1991 7276 7280
47. J. SantaLucia Jr., and D. Hicks The thermodynamics of DNA structural motifs Annu Rev Biophys Biomol Struct 33 2004 415 440
48. T. Itabashi, C. Maesawa, M. Uchiyama, T. Higuchi, and T. Masuda Quantitative detection of mutant alleles of the K-ras gene with minor groove binder-conjugated fluorogenic DNA probes Int J Oncol 24 2004 687 696
49. B. Denys, H. El Housni, F. Nollet, B. Verhasselt, and J. Philippe A real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2V617F mutation using a locked nucleic acid-modified oligonucleotide J Mol Diagn 12 2010 512 519
50. J.D. Banfield, and A.E. Raftery Model-based gaussian and non-gaussian clustering Biometrics 49 1993 803 821
51. H.D. Do, and A. Dobrovic Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization Clin Chem 61 2015 64 71
52. R.Y. Kim, H. Xu, S. Myllykangas, and H. Ji Genetic-based biomarkers and next-generation sequencing: the future of personalized care in colorectal cancer Per Med 8 2011 331 345
53. B. Vogelstein, and K.W. Kinzler Digital PCR Proc Natl Acad Sci U S A 96 1999 9236 9241
54. E. Castellanos-Rizaldos, C. Paweletz, C. Song, G.R. Oxnard, H. Mamon, P.A. Jänne, and G.M. Makrigiorgos Enhanced ratio of signals enables digital mutation scanning for rare allele detection J Mol Diagn 17 2015 284 292
55. P.J. Lamy, F. Castan, N. Lozano, C. Montélion, P. Audran, F. Bibeau, S. Roques, F. Montels, and A.C. Laberenne Next-generation genotyping by digital PCR to detect and quantify the BRAF V600E mutation in melanoma biopsies J Mol Diagn 17 2015 366 373
56. A. Skorokhod, P. Helmbold, B. Brors, P. Schirmacher, A. Enk, and R. Penzel Automated universal BRAF state detection within the activation segment in skin metastases by pyrosequencing-based assay U-BRAF(V600) PLoS One 8 2013 e59221
57. P. Szankasi, N.S. Reading, C.P. Vaughn, J.T. Prchal, D.W. Bahler, and T.W. Kelley A quantitative allele-specific PCR test for the BRAF V600E mutation using a single heterozygous control plasmid for quantitation: a model for qPCR testing without standard curves J Mol Diagn 15 2013 248 254
58. D. Chen, J.F. Huang, H. Xia, G.J. Duan, Z.R. Chuai, Z. Yang, W.L. Fu, and Q. Huang High-sensitivity PCR method for detecting BRAF V600E mutations in metastatic colorectal cancer using LNA/DNA chimeras to block wild-type alleles Anal Bioanal Chem 406 2014 2477 2487
59. A. How-Kit, C. Lebbé, A. Bousard, A. Daunay, N. Mazaleyrat, C. Daviaud, S. Mourah, and J. Tost Ultrasensitive detection and identification of BRAF V600 mutations in fresh frozen, FFPE, and plasma samples of melanoma patients by E-ice-COLD-PCR Anal Bioanal Chem 406 2014 5513 5520
60. M.F. Sanmamed, S. Fernández-Landázuri, C. Rodriguez, R. Zárate, M.D. Lozano, L. Zubiri, J.L. Perez-Gracia, S. Martin-Algarra, and A. González Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors Clin Chem 61 2015 297 304
61. K.M. Ilieva, I. Correa, D.H. Josephs, P. Karagiannis, I.U. Egbuniwe, M.J. Cafferkey, J.F. Spicer, M. Harries, F.O. Nestle, K.E. Lacy, and S.N. Karagiannis Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma Mol Cancer Ther 13 2014 2769 2783